Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

计划入组 65 人 · 首次发布于 2024 年 7 月 3 日

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

计划入组 20 人 · 首次发布于 2026 年 3 月 2 日

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

计划入组 192 人 · 首次发布于 2023 年 8 月 21 日

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Pre-Transplant MRD Status Significantly Impacts Survival Outcomes in AML and MDS Patients

NGS-MRD Monitoring Predicts Relapse Risk in AML Patients Post-Transplant

MRD Assessment in Myeloma Trials Shows Increasing Use but Lacks Standardization